SCHEMBL1474399

SCHEMBL1474399

O=C(NCCCn1ccnc1)c1cc(-c2ccncc2)on1

nearest known ligand 0.86

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.86
RAB9A P51151 4/20 0.86
SMN1; SMN2 Q16637 4/20 0.86
NPC1 O15118 3/20 0.86
HTT P42858 1/20 0.86
HIF1A Q16665 1/20 0.86
ALDH1A1 P00352 1/20 0.82
GAA P10253 1/20 0.82
KDM4E B2RXH2 3/20 0.78
NFKB1 P19838 1/20 0.74
NFKB2 Q00653 1/20 0.74
RELA Q04206 1/20 0.74
MAPK1 P28482 1/20 0.72
GLA P06280 1/20 0.66
HSD17B10 Q99714 1/20 0.66
MEN1 O00255 1/20 0.55
TSHR P16473 1/20 0.55
KMT2A Q03164 1/20 0.55
NAMPT P43490 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1179277 0.92 LMNA (1.00) LMNARAB9ASMN1; SMN2NPC1HTT
SCHEMBL1476641 0.91 LMNA (0.83) LMNARAB9ASMN1; SMN2NPC1HTT
SCHEMBL1178691 0.90 LMNA (0.81) LMNARAB9ASMN1; SMN2NPC1HTT
SCHEMBL1179061 0.90 LMNA (0.81) LMNARAB9ASMN1; SMN2NPC1HTT
SCHEMBL1177752 0.90 LMNA (0.81) LMNARAB9ASMN1; SMN2NPC1HTT
SCHEMBL1178247 0.90 LMNA (1.00) LMNARAB9ASMN1; SMN2NPC1HTT
SCHEMBL1474847 0.90 LMNA (0.77) LMNARAB9ASMN1; SMN2NPC1HTT
SCHEMBL1178912 0.89 LMNA (0.76) LMNARAB9ASMN1; SMN2NPC1HTT
SCHEMBL1179553 0.88 KDM4E (1.00) LMNARAB9ASMN1; SMN2NPC1HTT
SCHEMBL1476364 0.87 LMNA (0.83) LMNARAB9ASMN1; SMN2NPC1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 LMNA 2934/4885RAB9A 2013/4885SMN1; SMN2 3980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.